Recursion Pharmaceuticals, Inc. (RXRX) Total liabilities 2020–2025
Recursion Pharmaceuticals, Inc. (RXRX) total liabilities at each fiscal year-end, per SEC filings.
$343.3MFY2025 · since FY2020: $56.6M → $343.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $343.3M | -17.0% |
| FY2024 | $413.8M | +117.5% |
| FY2023 | $190.3M | -11.7% |
| FY2022 | $215.5M | +219.7% |
| FY2021 | $67.4M | +19.2% |
| FY2020 | $56.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More RXRX financial trends
RXRX RevenueRXRX Net incomeRXRX Net marginRXRX Gross profitRXRX Gross marginRXRX Operating incomeRXRX Operating marginRXRX Operating cash flowRXRX Free cash flowRXRX Capital expendituresRXRX Return on equityRXRX Stock buybacksRXRX Dividends paidRXRX Total assetsRXRX Shareholders’ equityRXRX overview →